aluates Reports

$ 0.0

Automative

Global Novel Coronavirus (COVID-19) Vaccine Market Research Report 2024

Published Date: July 2024

Report Code: QYRE-Auto-29K5790

Global Novel Coronavirus COVID 19 Vaccine Market Size Status and Forecast 2022 2028

BUY CHAPTERS

Global Novel Coronavirus (COVID-19) Vaccine Market Research Report 2024

Code: QYRE-Auto-29K5790

Report

July 2024

Pages:108

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

Novel Coronavirus (COVID-19) Vaccine Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Novel Coronavirus (COVID-19) Vaccine Market

The global Novel Coronavirus (COVID-19) Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Novel Coronavirus (COVID-19) Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Novel Coronavirus (COVID-19) Vaccine.

Report Scope

The Novel Coronavirus (COVID-19) Vaccine market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Novel Coronavirus (COVID-19) Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Novel Coronavirus (COVID-19) Vaccine companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Novel Coronavirus (COVID-19) Vaccine Market Report

Report Metric	Details
Report Name	Novel Coronavirus (COVID-19) Vaccine Market
CAGR	5%
Segment by Type	DNA RNA Others
Segment by Application	Mild Symptom Patient Critically Ill Patient
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Inovio Pharmaceuticals, Takis Biotech (Evvivax), Zydus Cadila, Codagenix, Inc., GeoVax, Inc., Bravovax, Janssen Pharmaceutical Companies, Altimmune, Vaxart, CanSino Biologics, ExpreS2ion Biotechnologies ApS, Clover Biopharmaceuticals, GSK, Vaxil Bio Ltd., Generex, Novavax, Inc., Sanofi Pasteur, Baylor, iBio, Inc., Moderna, Inc., Curevac, ImmunoPrecise
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Novel Coronavirus (COVID-19) Vaccine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Novel Coronavirus (COVID-19) Vaccine Market report?

Ans: The main players in the Novel Coronavirus (COVID-19) Vaccine Market are Inovio Pharmaceuticals, Takis Biotech (Evvivax), Zydus Cadila, Codagenix, Inc., GeoVax, Inc., Bravovax, Janssen Pharmaceutical Companies, Altimmune, Vaxart, CanSino Biologics, ExpreS2ion Biotechnologies ApS, Clover Biopharmaceuticals, GSK, Vaxil Bio Ltd., Generex, Novavax, Inc., Sanofi Pasteur, Baylor, iBio, Inc., Moderna, Inc., Curevac, ImmunoPrecise

What are the Application segmentation covered in the Novel Coronavirus (COVID-19) Vaccine Market report?

Ans: The Applications covered in the Novel Coronavirus (COVID-19) Vaccine Market report are Mild Symptom Patient, Critically Ill Patient

What are the Type segmentation covered in the Novel Coronavirus (COVID-19) Vaccine Market report?

Ans: The Types covered in the Novel Coronavirus (COVID-19) Vaccine Market report are DNA, RNA, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 DNA

1.2.3 RNA

1.2.4 Others

1.3 Market by Application

1.3.1 Global Novel Coronavirus (COVID-19) Vaccine Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Mild Symptom Patient

1.3.3 Critically Ill Patient

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Novel Coronavirus (COVID-19) Vaccine Market Perspective (2019-2030)

2.2 Novel Coronavirus (COVID-19) Vaccine Growth Trends by Region

2.2.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Novel Coronavirus (COVID-19) Vaccine Historic Market Size by Region (2019-2024)

2.2.3 Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Region (2025-2030)

2.3 Novel Coronavirus (COVID-19) Vaccine Market Dynamics

2.3.1 Novel Coronavirus (COVID-19) Vaccine Industry Trends

2.3.2 Novel Coronavirus (COVID-19) Vaccine Market Drivers

2.3.3 Novel Coronavirus (COVID-19) Vaccine Market Challenges

2.3.4 Novel Coronavirus (COVID-19) Vaccine Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Novel Coronavirus (COVID-19) Vaccine Players by Revenue

3.1.1 Global Top Novel Coronavirus (COVID-19) Vaccine Players by Revenue (2019-2024)

3.1.2 Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Players (2019-2024)

3.2 Global Novel Coronavirus (COVID-19) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Novel Coronavirus (COVID-19) Vaccine Revenue

3.4 Global Novel Coronavirus (COVID-19) Vaccine Market Concentration Ratio

3.4.1 Global Novel Coronavirus (COVID-19) Vaccine Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Novel Coronavirus (COVID-19) Vaccine Revenue in 2023

3.5 Novel Coronavirus (COVID-19) Vaccine Key Players Head office and Area Served

3.6 Key Players Novel Coronavirus (COVID-19) Vaccine Product Solution and Service

3.7 Date of Enter into Novel Coronavirus (COVID-19) Vaccine Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Novel Coronavirus (COVID-19) Vaccine Breakdown Data by Type

4.1 Global Novel Coronavirus (COVID-19) Vaccine Historic Market Size by Type (2019-2024)

4.2 Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Type (2025-2030)

5 Novel Coronavirus (COVID-19) Vaccine Breakdown Data by Application

5.1 Global Novel Coronavirus (COVID-19) Vaccine Historic Market Size by Application (2019-2024)

5.2 Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Novel Coronavirus (COVID-19) Vaccine Market Size (2019-2030)

6.2 North America Novel Coronavirus (COVID-19) Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2019-2024)

6.4 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Novel Coronavirus (COVID-19) Vaccine Market Size (2019-2030)

7.2 Europe Novel Coronavirus (COVID-19) Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2019-2024)

7.4 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size (2019-2030)

8.2 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2019-2024)

8.4 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Novel Coronavirus (COVID-19) Vaccine Market Size (2019-2030)

9.2 Latin America Novel Coronavirus (COVID-19) Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2019-2024)

9.4 Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size (2019-2030)

10.2 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2019-2024)

10.4 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Inovio Pharmaceuticals

11.1.1 Inovio Pharmaceuticals Company Detail

11.1.2 Inovio Pharmaceuticals Business Overview

11.1.3 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Introduction

11.1.4 Inovio Pharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.1.5 Inovio Pharmaceuticals Recent Development

11.2 Takis Biotech (Evvivax)

11.2.1 Takis Biotech (Evvivax) Company Detail

11.2.2 Takis Biotech (Evvivax) Business Overview

11.2.3 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Introduction

11.2.4 Takis Biotech (Evvivax) Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.2.5 Takis Biotech (Evvivax) Recent Development

11.3 Zydus Cadila

11.3.1 Zydus Cadila Company Detail

11.3.2 Zydus Cadila Business Overview

11.3.3 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Introduction

11.3.4 Zydus Cadila Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.3.5 Zydus Cadila Recent Development

11.4 Codagenix, Inc.

11.4.1 Codagenix, Inc. Company Detail

11.4.2 Codagenix, Inc. Business Overview

11.4.3 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction

11.4.4 Codagenix, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.4.5 Codagenix, Inc. Recent Development

11.5 GeoVax, Inc.

11.5.1 GeoVax, Inc. Company Detail

11.5.2 GeoVax, Inc. Business Overview

11.5.3 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction

11.5.4 GeoVax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.5.5 GeoVax, Inc. Recent Development

11.6 Bravovax

11.6.1 Bravovax Company Detail

11.6.2 Bravovax Business Overview

11.6.3 Bravovax Novel Coronavirus (COVID-19) Vaccine Introduction

11.6.4 Bravovax Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.6.5 Bravovax Recent Development

11.7 Janssen Pharmaceutical Companies

11.7.1 Janssen Pharmaceutical Companies Company Detail

11.7.2 Janssen Pharmaceutical Companies Business Overview

11.7.3 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Introduction

11.7.4 Janssen Pharmaceutical Companies Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.7.5 Janssen Pharmaceutical Companies Recent Development

11.8 Altimmune

11.8.1 Altimmune Company Detail

11.8.2 Altimmune Business Overview

11.8.3 Altimmune Novel Coronavirus (COVID-19) Vaccine Introduction

11.8.4 Altimmune Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.8.5 Altimmune Recent Development

11.9 Vaxart

11.9.1 Vaxart Company Detail

11.9.2 Vaxart Business Overview

11.9.3 Vaxart Novel Coronavirus (COVID-19) Vaccine Introduction

11.9.4 Vaxart Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.9.5 Vaxart Recent Development

11.10 CanSino Biologics

11.10.1 CanSino Biologics Company Detail

11.10.2 CanSino Biologics Business Overview

11.10.3 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Introduction

11.10.4 CanSino Biologics Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.10.5 CanSino Biologics Recent Development

11.11 ExpreS2ion Biotechnologies ApS

11.11.1 ExpreS2ion Biotechnologies ApS Company Detail

11.11.2 ExpreS2ion Biotechnologies ApS Business Overview

11.11.3 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Introduction

11.11.4 ExpreS2ion Biotechnologies ApS Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.11.5 ExpreS2ion Biotechnologies ApS Recent Development

11.12 Clover Biopharmaceuticals

11.12.1 Clover Biopharmaceuticals Company Detail

11.12.2 Clover Biopharmaceuticals Business Overview

11.12.3 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Introduction

11.12.4 Clover Biopharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.12.5 Clover Biopharmaceuticals Recent Development

11.13 GSK

11.13.1 GSK Company Detail

11.13.2 GSK Business Overview

11.13.3 GSK Novel Coronavirus (COVID-19) Vaccine Introduction

11.13.4 GSK Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.13.5 GSK Recent Development

11.14 Vaxil Bio Ltd.

11.14.1 Vaxil Bio Ltd. Company Detail

11.14.2 Vaxil Bio Ltd. Business Overview

11.14.3 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Introduction

11.14.4 Vaxil Bio Ltd. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.14.5 Vaxil Bio Ltd. Recent Development

11.15 Generex

11.15.1 Generex Company Detail

11.15.2 Generex Business Overview

11.15.3 Generex Novel Coronavirus (COVID-19) Vaccine Introduction

11.15.4 Generex Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.15.5 Generex Recent Development

11.16 Novavax, Inc.

11.16.1 Novavax, Inc. Company Detail

11.16.2 Novavax, Inc. Business Overview

11.16.3 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction

11.16.4 Novavax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.16.5 Novavax, Inc. Recent Development

11.17 Sanofi Pasteur

11.17.1 Sanofi Pasteur Company Detail

11.17.2 Sanofi Pasteur Business Overview

11.17.3 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Introduction

11.17.4 Sanofi Pasteur Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.17.5 Sanofi Pasteur Recent Development

11.18 Baylor

11.18.1 Baylor Company Detail

11.18.2 Baylor Business Overview

11.18.3 Baylor Novel Coronavirus (COVID-19) Vaccine Introduction

11.18.4 Baylor Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.18.5 Baylor Recent Development

11.19 iBio, Inc.

11.19.1 iBio, Inc. Company Detail

11.19.2 iBio, Inc. Business Overview

11.19.3 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction

11.19.4 iBio, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.19.5 iBio, Inc. Recent Development

11.20 Moderna, Inc.

11.20.1 Moderna, Inc. Company Detail

11.20.2 Moderna, Inc. Business Overview

11.20.3 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction

11.20.4 Moderna, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.20.5 Moderna, Inc. Recent Development

11.21 Curevac

11.21.1 Curevac Company Detail

11.21.2 Curevac Business Overview

11.21.3 Curevac Novel Coronavirus (COVID-19) Vaccine Introduction

11.21.4 Curevac Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.21.5 Curevac Recent Development

11.22 ImmunoPrecise

11.22.1 ImmunoPrecise Company Detail

11.22.2 ImmunoPrecise Business Overview

11.22.3 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Introduction

11.22.4 ImmunoPrecise Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

11.22.5 ImmunoPrecise Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

Table 1. Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of DNA

Table 3. Key Players of RNA

Table 4. Key Players of Others

Table 5. Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Region (2019-2024)

Table 9. Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Region (2025-2030)

Table 11. Novel Coronavirus (COVID-19) Vaccine Market Trends

Table 12. Novel Coronavirus (COVID-19) Vaccine Market Drivers

Table 13. Novel Coronavirus (COVID-19) Vaccine Market Challenges

Table 14. Novel Coronavirus (COVID-19) Vaccine Market Restraints

Table 15. Global Novel Coronavirus (COVID-19) Vaccine Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Players (2019-2024)

Table 17. Global Top Novel Coronavirus (COVID-19) Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Coronavirus (COVID-19) Vaccine as of 2023)

Table 18. Ranking of Global Top Novel Coronavirus (COVID-19) Vaccine Companies by Revenue (US$ Million) in 2023

Table 19. Global 5 Largest Players Market Share by Novel Coronavirus (COVID-19) Vaccine Revenue (CR5 and HHI) & (2019-2024)

Table 20. Key Players Headquarters and Area Served

Table 21. Key Players Novel Coronavirus (COVID-19) Vaccine Product Solution and Service

Table 22. Date of Enter into Novel Coronavirus (COVID-19) Vaccine Market

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type (2019-2024)

Table 26. Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type (2025-2030)

Table 28. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2019-2024)

Table 30. Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2025-2030)

Table 32. North America Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 33. North America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2019-2024) & (US$ Million)

Table 34. North America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2025-2030) & (US$ Million)

Table 35. Europe Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2019-2024) & (US$ Million)

Table 37. Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2025-2030) & (US$ Million)

Table 38. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 39. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2019-2024) & (US$ Million)

Table 40. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2025-2030) & (US$ Million)

Table 41. Latin America Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 42. Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2019-2024) & (US$ Million)

Table 43. Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2025-2030) & (US$ Million)

Table 44. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2019-2024) & (US$ Million)

Table 46. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2025-2030) & (US$ Million)

Table 47. Inovio Pharmaceuticals Company Detail

Table 48. Inovio Pharmaceuticals Business Overview

Table 49. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product

Table 50. Inovio Pharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 51. Inovio Pharmaceuticals Recent Development

Table 52. Takis Biotech (Evvivax) Company Detail

Table 53. Takis Biotech (Evvivax) Business Overview

Table 54. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Product

Table 55. Takis Biotech (Evvivax) Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 56. Takis Biotech (Evvivax) Recent Development

Table 57. Zydus Cadila Company Detail

Table 58. Zydus Cadila Business Overview

Table 59. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Product

Table 60. Zydus Cadila Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 61. Zydus Cadila Recent Development

Table 62. Codagenix, Inc. Company Detail

Table 63. Codagenix, Inc. Business Overview

Table 64. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Product

Table 65. Codagenix, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 66. Codagenix, Inc. Recent Development

Table 67. GeoVax, Inc. Company Detail

Table 68. GeoVax, Inc. Business Overview

Table 69. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Product

Table 70. GeoVax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 71. GeoVax, Inc. Recent Development

Table 72. Bravovax Company Detail

Table 73. Bravovax Business Overview

Table 74. Bravovax Novel Coronavirus (COVID-19) Vaccine Product

Table 75. Bravovax Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 76. Bravovax Recent Development

Table 77. Janssen Pharmaceutical Companies Company Detail

Table 78. Janssen Pharmaceutical Companies Business Overview

Table 79. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Product

Table 80. Janssen Pharmaceutical Companies Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 81. Janssen Pharmaceutical Companies Recent Development

Table 82. Altimmune Company Detail

Table 83. Altimmune Business Overview

Table 84. Altimmune Novel Coronavirus (COVID-19) Vaccine Product

Table 85. Altimmune Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 86. Altimmune Recent Development

Table 87. Vaxart Company Detail

Table 88. Vaxart Business Overview

Table 89. Vaxart Novel Coronavirus (COVID-19) Vaccine Product

Table 90. Vaxart Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 91. Vaxart Recent Development

Table 92. CanSino Biologics Company Detail

Table 93. CanSino Biologics Business Overview

Table 94. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Product

Table 95. CanSino Biologics Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 96. CanSino Biologics Recent Development

Table 97. ExpreS2ion Biotechnologies ApS Company Detail

Table 98. ExpreS2ion Biotechnologies ApS Business Overview

Table 99. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Product

Table 100. ExpreS2ion Biotechnologies ApS Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 101. ExpreS2ion Biotechnologies ApS Recent Development

Table 102. Clover Biopharmaceuticals Company Detail

Table 103. Clover Biopharmaceuticals Business Overview

Table 104. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product

Table 105. Clover Biopharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 106. Clover Biopharmaceuticals Recent Development

Table 107. GSK Company Detail

Table 108. GSK Business Overview

Table 109. GSK Novel Coronavirus (COVID-19) Vaccine Product

Table 110. GSK Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 111. GSK Recent Development

Table 112. Vaxil Bio Ltd. Company Detail

Table 113. Vaxil Bio Ltd. Business Overview

Table 114. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Product

Table 115. Vaxil Bio Ltd. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 116. Vaxil Bio Ltd. Recent Development

Table 117. Generex Company Detail

Table 118. Generex Business Overview

Table 119. Generex Novel Coronavirus (COVID-19) Vaccine Product

Table 120. Generex Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 121. Generex Recent Development

Table 122. Novavax, Inc. Company Detail

Table 123. Novavax, Inc. Business Overview

Table 124. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Product

Table 125. Novavax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 126. Novavax, Inc. Recent Development

Table 127. Sanofi Pasteur Company Detail

Table 128. Sanofi Pasteur Business Overview

Table 129. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Product

Table 130. Sanofi Pasteur Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 131. Sanofi Pasteur Recent Development

Table 132. Baylor Company Detail

Table 133. Baylor Business Overview

Table 134. Baylor Novel Coronavirus (COVID-19) Vaccine Product

Table 135. Baylor Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 136. Baylor Recent Development

Table 137. iBio, Inc. Company Detail

Table 138. iBio, Inc. Business Overview

Table 139. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Product

Table 140. iBio, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 141. iBio, Inc. Recent Development

Table 142. Moderna, Inc. Company Detail

Table 143. Moderna, Inc. Business Overview

Table 144. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Product

Table 145. Moderna, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 146. Moderna, Inc. Recent Development

Table 147. Curevac Company Detail

Table 148. Curevac Business Overview

Table 149. Curevac Novel Coronavirus (COVID-19) Vaccine Product

Table 150. Curevac Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 151. Curevac Recent Development

Table 152. ImmunoPrecise Company Detail

Table 153. ImmunoPrecise Business Overview

Table 154. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Product

Table 155. ImmunoPrecise Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024) & (US$ Million)

Table 156. ImmunoPrecise Recent Development

Table 157. Research Programs/Design for This Report

Table 158. Key Data Information from Secondary Sources

Table 159. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Novel Coronavirus (COVID-19) Vaccine Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Type: 2023 VS 2030

Figure 3. DNA Features

Figure 4. RNA Features

Figure 5. Others Features

Figure 6. Global Novel Coronavirus (COVID-19) Vaccine Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Application: 2023 VS 2030

Figure 8. Mild Symptom Patient Case Studies

Figure 9. Critically Ill Patient Case Studies

Figure 10. Novel Coronavirus (COVID-19) Vaccine Report Years Considered

Figure 11. Global Novel Coronavirus (COVID-19) Vaccine Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 12. Global Novel Coronavirus (COVID-19) Vaccine Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Region: 2023 VS 2030

Figure 14. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Players in 2023

Figure 15. Global Top Novel Coronavirus (COVID-19) Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Coronavirus (COVID-19) Vaccine as of 2023)

Figure 16. The Top 10 and 5 Players Market Share by Novel Coronavirus (COVID-19) Vaccine Revenue in 2023

Figure 17. North America Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 18. North America Novel Coronavirus (COVID-19) Vaccine Market Share by Country (2019-2030)

Figure 19. United States Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. Canada Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Europe Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Europe Novel Coronavirus (COVID-19) Vaccine Market Share by Country (2019-2030)

Figure 23. Germany Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. France Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. U.K. Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Italy Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Russia Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Nordic Countries Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Share by Region (2019-2030)

Figure 31. China Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Japan Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. South Korea Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Southeast Asia Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. India Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Australia Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Latin America Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Latin America Novel Coronavirus (COVID-19) Vaccine Market Share by Country (2019-2030)

Figure 39. Mexico Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Brazil Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Share by Country (2019-2030)

Figure 43. Turkey Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Saudi Arabia Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Inovio Pharmaceuticals Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 46. Takis Biotech (Evvivax) Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 47. Zydus Cadila Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 48. Codagenix, Inc. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 49. GeoVax, Inc. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 50. Bravovax Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 51. Janssen Pharmaceutical Companies Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 52. Altimmune Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 53. Vaxart Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 54. CanSino Biologics Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 55. ExpreS2ion Biotechnologies ApS Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 56. Clover Biopharmaceuticals Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 57. GSK Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 58. Vaxil Bio Ltd. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 59. Generex Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 60. Novavax, Inc. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 61. Sanofi Pasteur Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 62. Baylor Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 63. iBio, Inc. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 64. Moderna, Inc. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 65. Curevac Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 66. ImmunoPrecise Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2019-2024)

Figure 67. Bottom-up and Top-down Approaches for This Report

Figure 68. Data Triangulation

Figure 69. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Novel Coronavirus (COVID-19) Vaccine Market Research Report 2024

Published Date: July 2024

Report Code: QYRE-Auto-29K5790

Global Novel Coronavirus (COVID-19) Vaccine Market Research Report 2024

FEATURED COMPANIES

Novel Coronavirus (COVID-19) Vaccine Market Size

Novel Coronavirus (COVID-19) Vaccine Market

Report Scope

Scope of Novel Coronavirus (COVID-19) Vaccine Market Report

Chapter Outline

FAQ for this report

Who are the main players in the Novel Coronavirus (COVID-19) Vaccine Market report?

What are the Application segmentation covered in the Novel Coronavirus (COVID-19) Vaccine Market report?

What are the Type segmentation covered in the Novel Coronavirus (COVID-19) Vaccine Market report?

FEATURED COMPANIES